About this trial
The primary purpose of this study is to determine the differences in response to treatment of complex regional pain syndrome with a closed-loop spinal cord stimulator if applied in the early phases (acute or subacute) versus the chronic phase.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years or older
neuromodulation naive patients with unilateral CRPS type 1 or type 2 (defined by Budapest Criteria)
pre-procedure psychological clearance
Disqualifiers
younger than 18 years
prior neuromodulation including spinal cord stimulation
prior dorsal root ganglion stimulation
prior peripheral nervous system stimulation
Trial design
Parallel
Treatments tested in this trial
Spinal Cord Stimulation Device
DeviceThe closed-loop spinal cord stimulation mechanism uses dynamic adjusting stimulation parameters based on real-time physiologic response and is uniquely positioned to mitigate the aberrant inflammatory and neurosensory processing and autonomic dysfunction driving CRPS and its progression between phases.
Treatment groups
Trial outcomes
Primary outcomes
Change in Complex Regional Pain Syndrome Severity Scores
(CRPS SS) This will be determined at baseline by the provider based on his diagnosis of the patient's condition, being acute and subacute or chronic. This is based on the presence or absence of 16 clinically-assessed signs and symptoms, and complements the diagnostic criteria for CRPS. A higher score indicates greater severity of the condition. This will be followed up at the 7 day trial period, 3 months and 6 months post procedure by evaluation.
Change in Target Activation Amplitude Levels by the Spinal Cord Stimulation Device
Spinal cord stimulation device parameters will be collected to determine if a lower voltage is required to treat acute phase of complex regional pain syndrome as compared to later phases. This will be conducted at follow up visits and analyzed by the medical device representative. The data will be pulled and analyzed to determine the activation point for each patient. This will be captured at the 7 day trial period, 3 months, and 6 months.
Secondary outcomes
Change in Prolactin Levels
We plan to include a physiological marker of pain response by assessing serum prolactin levels, which are linked to dopamine levels in the brain. We will use prolactin as a convenient marker of abnormal dopamine levels due to chronic pain and the response to spinal cord stimulation treatment as an objective quantifiable metric of success with treatment. We will collect this via blood draw at our lab at baseline, at the 7 day trial period, and 3 months.
Visual Analogue Pain Scale
(VAS) This will be used to determine the pain intensity the patient is experiencing. It will be on a scale from 0-10, 0 being no pain and 10 being the worst pain.
Quality of Life Questionnaire
(EQ-5D-5L) Used to capture quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A lower score would indicate a severe score and the patient has a low quality of life. The patient also rates how good or bad their health is on a scale of 0-100, 100 being the best health and 0 being the worst health they could imagine.
Patient Reported Outcomes Measurement Information System-29 v 2.1
(PROMIS-29v2.1) Used to assess pain intensity using a single 0-10 numeric rating item and seven health domains: physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.